CannaPharmaRx Stops Issuing Shares Under Previously Effective S-1

Rhea-AI Summary

CannaPharmaRx (OTC PINK: CPMD) announced it will cease issuing shares under its S-1 registration, which included 135 million shares filed in May 2021. This decision follows the company's shift towards alternative funding and leasing new facilities, aiming for significant cash flow. CEO Nick Colvin emphasized that discontinuing the S-1 will limit shareholder dilution, which is a critical move for investor confidence. The company is focused on becoming a leader in efficient cannabis production in Canada through advanced facilities and technology.

Positive

• CannaPharmaRx has received alternative funding, reducing reliance on share issuance.
• The cessation of the S-1 will limit potential shareholder dilution.
• Plans for new facilities are expected to generate significant cash flow.

Negative

• None.

CALGARY, AB / ACCESSWIRE / February 8, 2022 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today that it will no longer will be issuing shares under the previously effective S-1.

The S-1 included 135,000,000 registered shares and was filed on May 15, 2021. The S-1 went effective on June 11, 2021.

"While some shares have been issued and converted previously under the S-1 to advance the company to the stage it is currently at, it no longer makes sense to utilize the shares still available. We have received alternative funding, leased new facilities, and will be able to generate significant cash flow moving forward. We believe this is an important step for investors, as it limits any further dilution from these shares," stated Nick Colvin, CEO of CannapharmaRx.

About CannapharmaRx, Inc.

CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx's business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.

Safe Harbor Statement

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are 'forward-looking information or statements.' Forward-looking information or statements can be identified by the use of words such as 'plans,' 'expects,' or 'does not expect,' 'is expected,' 'estimates,' 'intends,' 'anticipates,' or 'does not anticipate,' or 'believes,' or variations of such words and phrases or statements that certain actions, events or results 'may,' 'could,' 'would,' 'might' or 'will' be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

Contact Information:
Brokers and Analysts:
Chesapeake Group
(410) 825-3930

SOURCE: CannaPharmaRx, Inc.

View source version on accesswire.com:
https://www.accesswire.com/687683/CannaPharmaRx-Stops-Issuing-Shares-Under-Previously-Effective-S-1

FAQ

Why did CannaPharmaRx stop issuing shares under the S-1?

CannaPharmaRx opted to stop issuing shares under the S-1 to limit shareholder dilution, having secured alternative funding and new facility leases.

What was included in the S-1 registration by CannaPharmaRx?

The S-1 registration filed by CannaPharmaRx included 135,000,000 registered shares.

When was the S-1 for CannaPharmaRx filed?

The S-1 was filed on May 15, 2021, and became effective on June 11, 2021.

What is CannaPharmaRx's focus after discontinuing the S-1?

CannaPharmaRx is focused on acquiring and developing efficient cannabis grow facilities in Canada.

What does the future hold for CannaPharmaRx after this announcement?

CannaPharmaRx aims to establish itself as a leader in cannabis production, leveraging new funding and facilities for cash flow generation.